AntibioTx has been invited to present recent positive results with ATx201 at the ‘2nd Inflammatory Skin Disease Summit’ symposium in New York the 16-20th November 2016. 

The ‘2nd Inflammatory Skin Disease Summit’ is a symposium that directly addresses and describes new developments and therapies for key inflammatory skin diseases, such as psoriasis, atopic dermatitis and an increasing number of other inflammatory conditions. 

The main purpose of the symposium is to update practicing dermatologist, MD-scientists and researchers in the field of treating skin diseases. The Symposium will feature internationally recognized researchers and will provide new research within skin infections and guidelines for future treatments improving clinical outcomes for the patients.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.